MiR200c targets IRS1 and suppresses prostate cancer cell growth.
By: Wenjing Su, Miao Xu, Xueqin Chen, Ling Nie, Ni Chen, Jing Gong, Mengni Zhang, Zhengzheng Su, Lei Huang, Qiao Zhou

Department of Pathology and Laboratory of Pathology, State Key Laboratory of Biotherapy; West China Hospital, West China Medical School, Sichuan University, Chengdu, P.R. China; Department of Pathology, Shandong Provincial Hospital, Shandong University, Jinan, P.R. China.
2014-12-9; doi: 10.1002/pros.22968
Abstract

Background

The downregulation of the tumor suppressor miR200c plays important roles in many malignant tumors. This study aims to show that miR200c is a posttranscriptional regulator of insulin receptor substrate 1 (IRS1) and over-expression of miR200c suppresses prostate cancer cell growth.

Methods

Bioinformatics analysis was used to show potential post-translational regulation of IRS1 by miR200c. Dual reporter gene assays were chosen to test the binding of miR200c to the potential seed sequences in IRS1 3'UTR. RT-PCR, Q-PCR and western blot were applied to determine the regulation effect of miR200c on IRS1. CCK8 assay, soft agar assay, trypan blue exclusion assay and flow cytometric analysis were used to measure the biological effects of miR200c on prostate cancer cell proliferation and apoptosis.

Results

The 449-455 nt, 3061-3067 nt, and 3096-3102 nt of the IRS1 3'-UTR were identified as three potential seed sequences for miR200c. MiR200c directly binds to IRS1 through the seed sequences in IRS1 3'-UTR. Artificial overexpression of miR200c significantly downregulated the mRNA and protein levels of IRS1, together with decreased cell proliferation and increased cell death of PC3 and DU145 cells.

Conclusions

Our results suggest that miR200c plays crucial roles in prostate cancer by post-transcriptional regulation of IRS1. The mir200c/IRS1 pathway may be a potential therapeutic target to prevent prostate cancer cell growth. Prostate 9999: 1-8, 2015. © 2015 Wiley Periodicals, Inc.



© 2015 Wiley Periodicals, Inc.

PMID:25683382






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements